Clinical Trial Update: Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of neoadjuvant and adjuvant capecitabine and oxaliplatin in patients with resectable liver metastases from colorectal cancer has been terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Liver Metastases

Drugs mentioned

• Capecitabine (capecitabine)
• Eloxatin (oxaliplatin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Liver Metastases, Recurrent Colon Cancer | Phase 2 | Status: TERMINATED